Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credits: Canva
Adenovirus, or what some people are calling the mystery disease is going to be the next worry in the UK, after superflu had already grappled the healthcare system. Along with H3N2 and its variant superclade K, people are now worrying about this mystery disease.
Adenovirus is highly contagious and causes mild cold or flu-like symptoms, though severe cases could lead to stomach flu and vomiting. Many describe this virus as 'heartier' than others. The reason is that the virus can survive longer on surfaces and even resist the common disinfectants used. This is what makes it highly transmissible.
As of now, there is no treatment for adenovirus, it could however be managed and monitored. What helps is regular handwashing and thorough cleaning of surfaces.
The good news is that cases of adenovirus are actually dropping in the UK, as confirmed lab reports. The cases last week were 1.2 per cent, whereas the week prior, it was at 1.7 per cent, as also reported by the Independent.
While a lot of the symptoms mimics of those in flu or COVID, including shortness of breath, a sore throat and or a runny nose. However, there are certain unique symptoms of adenovirus that include:
Other rare symptoms could also include impact on your bladder or nervous system. As viruses in your bladder can also cause urinary tract infections, and the same virus in your nervous system can cause condition that can affect your brain. These conditions also include encephalitis and meningitis.
The symptoms usually start to subside within two days, however, if the symptoms stay even after three days without any relief, it might be a red flag. The best thing to do during such a situation is to go consult your GP.
Also Read: Unique Symptoms Of Mysterious Adenovirus And How Long Infection Now Last
Experts have noted that due to its ability to stay longer in the environment and being highly transmissible, it is in fact, spreading faster than flu and COVID. Eric Sachinwalla, Jefferson Health's medical director said that this virus is still unfamiliar and thus not much can actually be done to treat adenovirus. Speaking to PhillyMad, he said, "It is pretty contagious because it is heartier than other viruses - soap and water, or everyday disinfectant, won't kill it, so it tends to live in the environment longer."
Since adenovirus spreads through close contact and is resistant to many everyday disinfectants, hygiene remains the key. The best way to stay safe is by avoiding close contact, especially with those who are unwell. You may also keep an eye on your symptoms, including your body temperature and take steps to prevent the virus from spreading by taking precautions, as well as getting the flu jab.
Credits: iStock
The World Health Organization (WHO) on December 24 prequalified two rapid antigen diagnostic tests (Ag-RDTs) for SARS-CoV-2. This virus is known to have caused COVID-19. As per the WHO, these two tests are called SD Biosensor STANDARD Q COVID-19 Ag Test and the ACON Biotech Flowflex SARS-CoV-2 Antigen Rapid Test (Self-Testing).
At first these tests got temporary emergency approval from the WHO during the pandemic. This was done so the countries could start using them quickly even though long-term data was limited. This emergency approval helped the tests reach over 100 countries when they were urgently needed.
The WHO has now given these tests full prequalification, which means it has a stronger and long-term approval. This means that the WHO has thoroughly checked and confirmed that the tests consistently meet global standards for quality, safety, and accuracy.
Even though WHO officially ended COVID-19 emergency phase over two years ago, the virus is still circulating globally. In fact, this year, we have seen variants of COVID-19 circulating around, causing the most unique symptoms, including razor-blade like throat. Variants like JN.1, Stratus, Nimbus, LP8.1, and BA.3.2 were all that we saw in 2025.
While the good news is that infection levels are relatively stable, but the virus has not completely disappeared and testing is still necessary, especially in poorer countries.
Many low-income countries do not have easy access to labs or expensive PCR testing. So there is still a need for a strong, but cheaper and reliable way to detect COVID-19, and these tests may as well do that.
However, it is important to note that rapid antigen tests are not replacement for PCR tests. They simply complement the PCR tests by allowing faster, on-the-spot decisions, especially when the lab capacity is limited.
Rapid antigen tests could help with spotting and stopping local outbreaks quickly, protecting high-risk people and healthcare workers, and staying prepared for future respiratory pandemics.
The WHO is also pushing for decentralized, quality-checked testing as part of universal healthcare and global health security, so countries aren’t caught unprepared when the next outbreak happens.
If you notice these following symptoms as noted by the Centers for Disease Control and Prevention (CDC), it is best that you get yourself a COVID-19 test:
Credits: iStock
As Delhi's air quality levels and pollution continues to worsen, and people struggle to breathe, countries like Singapore, the United Kingdom, and Canada issued advisories for their citizens travelling to the capital city. However, the capital city's crisis continues to remain ignore, though CM Rekha Gupta did hold a review meeting on the same on Monday, with a follow-up scheduled on Thursday.
Singapore High Commission issued an advisory, which stated:
On 13 December 2025: The Indian Central Pollution Control Board invoked Stage 4, the highest level, of the Graded Response Action Plan (GRAP) in the Delhi National Capital Region. Under GRAP 4, construction and industrial activities are heavily restricted, and schools and offices are encouraged to shift to hybrid format. The Delhi authorities have urged residents to stay indoors, especially children and those with respiratory or cardiac ailments, and to use masks if stepping out. In this regard, the High Commission urges Singapore nationals in the Delhi National Capital Region to pay heed to this advice.
We also note that given the low visibility, flights to and from the Delhi National Capital Region are likely to be affected. The Indira Gandhi International Airport and several airlines have issued advisories. Travellers should take note of this, and check with the respective airlines for updates.
UK's Foreign, Commonwealth & Development Office (FCDO) warned that air pollution could lead to serious health threats for those living in northern India, especially between the months of October and February. The UK advisory also stressed on the health of pregnant women and people with any heart or respiratory. The advisory noted that they must seek medical advice before travelling to India.
The statement read: Children, the elderly and those with pre-existing medical conditions may be especially affected. If you’re pregnant or have a respiratory or heart condition you may wish to consult a medical practitioner before you travel.
Canada too issued a similar notice, advising, especially those who are already struggling with respiratory issues and to continuously monitor air quality levels. The notice also highlighted the pollution that is caused by fog and smoke trends that are increasing in urban areas like Delhi, especially during the winters.
The advisory read: Smoke haze and other types of air pollution can be extremely hazardous in urban areas and cities such as Delhi. It’s typically at its worst in winter. In rural areas, air quality can be affected by agricultural burning. Dust storms also occur across northern India. Monitor air pollution levels, which change quickly, especially if you suffer from respiratory ailments or have pre-existing medical conditions.
As of today, Delhi's air quality remained in "very poor" category, and the AQI stood at 342 at 8am, as per the Central Pollution Control Board. The 24-hour average AQI was logged at 412 under the "severe" category on Tuesday evening when Delhi's quality peaked to record the fourth severe air day in the month of December.
© 2024 Bennett, Coleman & Company Limited